The effect of erythropoiesis‑stimulating agents on lung cancer patients: a meta‑analysis
Wirkung erythropoese-stimulierender Agenzien bei Lungenkrebspatient:innen: Meta-Analyse
Clinical and Experimental Medicine · 05.07.2024 · 24 (1)
DOI: 10.1007/s10238-024-01391-3 ↗Auf einen Blick
Eine Meta-Analyse von RCTs bei Lungenkrebs zeigte: ESAs senkten den Transfusionsbedarf, erhöhten aber thrombotische vaskuläre Ereignisse. Die Mortalität war insgesamt nicht erhöht, teils sogar niedriger.
Fragestellung
Welchen Effekt haben erythropoese-stimulierende Agenzien (ESAs) bei Patient:innen mit Lungenkrebs auf Anämie-bezogene Endpunkte und Risiken?
Methode
Meta-Analyse randomisierter kontrollierter Studien aus PubMed, Embase, Web of Science und Cochrane Library von 2000 bis 2023.
Ergebnisse
8 Studien mit 4.240 Patient:innen: Mortalität RR 0,96 (95 %-KI 0,92–0,99), nach Entfernen von Pere 2020 RR 0,99 (95 %-KI 0,92–1,06). Thrombotische vaskuläre Ereignisse RR 1,40 (95 %-KI 1,13–1,72); Transfusionsbedarf RR 0,56 (95 %-KI 0,44–0,72).
Schlussfolgerung der Autor:innen
Die Autor:innen folgern, dass ESAs die Mortalität bei Lungenkrebs nicht erhöhen oder das Sterberisiko senken können und den Transfusionsbedarf reduzieren, jedoch thrombotische vaskuläre Nebenwirkungen erhöhen können.
Kernaussagen
- Mortalität insgesamt RR 0,96 (95 %-KI 0,92–0,99)
- Thrombotische vaskuläre Ereignisse RR 1,40 (95 %-KI 1,13–1,72)
- Transfusionsbedarf RR 0,56 (95 %-KI 0,44–0,72)
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Metaanalyse in der Zeitschrift Clinical and Experimental Medicine, online erschienen am 05.07.2024. Verfasst von Zhenhua Tong und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Research and Training, General Hospital of Northern Theater Command, No. 83, Wenhua Road, Shenyang, 110016, China. Hauptthemen laut MEDLINE: Anemia, Hematinics, Lung Neoplasms, Randomized Controlled Trials as Topic. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Previous studies have demonstrated that erythropoiesis-stimulating agents (ESAs) can reduce anemia and improve quality of life in cancer patients, but ESAs may increase mortality. Therefore, we conducted a meta-analysis of randomized controlled trials (RCT) comparing the effect and risk of ESAs about the prevention or treatment of anemia in cancer patients. Four databases including PubMed, Embase, Web of science and Cochrane Library were searched for published RCTS on ESAs in the treatment of anemia in lung cancer patients from 2000 to 2023. Endpoints including mortality, incidence of thrombotic vascular events, blood transfusion requirement, and incidence of adverse events. Our meta-analysis included 8 studies, with a sample size of 4240 patients, including 2548 patients in the ESAs group and 1692 patients in the control group. The risk of mortality was lower in patients using ESAs than control group (RR 0.96, 95% CI 0.92–0.99, P = 0.02). But there was no significant difference in the risk of mortality between the patients using ESAs and controls (RR 0.99, 95% CI 0.92–1.06, P = 0.69) after removing Pere 2020. Subgroup analysis found that patients diagnosed with small cell lung cancer (SCLC) (RR 1.00, 95% CI 0.92–1.08, P = 0.16) or non-small cell lung cancer (NSCLC) (RR 1.01, 95% CI 0.87–1.17, P = 0.13) were no significant difference in mortality rate. The thrombotic vascular events increase in patients using ESAs than control group (RR 1.40, 95% CI 1.13–1.72, P = 0.002). The blood transfusion requirement of ESAs group was lower than control group (RR 0.56, 95% CI 0.44–0.72, P < 0.00001). And the subgroups of Darbepoetin alfa (RR 0.57, 95% CI 0.41–0.79, P = 0.003) and Epoetin alfa (RR 0.68, 95% CI 0.47–0.99, P = 0.01) had lower transfusion requirements than the control group. In the SCLC subgroup (RR 0.51, 95% CI 0.40–0.65, P = 0.34), blood transfusion requirements were lower in the ESAs group, but there was no significant difference between the subgroup of patients with NSCLC (RR 0.61, 95% CI 0.36–1.04, P = 0.009). There was no statistically significant difference between the two groups in the incidence of adverse reactions (RR 0.98, 95% CI 0.95–1.00, P = 0.10). In conclusion, ESAs does not increase the mortality of lung cancer patients or may reduce the risk of death, and can reduce the need for blood transfusion, although ESA can increase the incidence of thrombotic vascular adverse events. Registration PROSPERO CRD42023463582.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Research and Training, General Hospital of Northern Theater Command, No. 83, Wenhua Road, Shenyang, 110016, China.
- Department of Pharmacy, The First Hospital of China Medical University, Shenyang, Liaoning, China.
- Shenyang Pharmaceutical University, Shenyang, Liaoning, China.
- Department of Pharmacy, General Hospital of Northern Theater Command, No. 83, Wenhua Road, Shenyang, 110016, China. sunxue88@163.com.
- Department of Cardiology, National Key Laboratory of Frigid Zone Cardiovascular Diseases (NKLFZCD), General Hospital of Northern Theater Command, No. 83, Wenhua Road, Shenyang, 110016, China. qibin202@163.com.
Zitieren
APA
Tong, Z., Xu, Z., Duan, Y., Sun, X., & Qi, B. (2024). The effect of erythropoiesis‑stimulating agents on lung cancer patients: a meta‑analysis. Clinical and Experimental Medicine, 24(1). https://doi.org/10.1007/s10238-024-01391-3
Vancouver
Tong Z, Xu Z, Duan Y, Sun X, Qi B. The effect of erythropoiesis‑stimulating agents on lung cancer patients: a meta‑analysis. Clinical and Experimental Medicine. 2024;24(1). doi:10.1007/s10238-024-01391-3
BibTeX
@article{Tong2024,
author = {Tong, Zhenhua and Xu, Zhumeng and Duan, Yaqi and Sun, Xue and Qi, Bin},
title = {The effect of erythropoiesis‑stimulating agents on lung cancer patients: a meta‑analysis},
journal = {Clinical and Experimental Medicine},
year = {2024},
volume = {24},
number = {1},
doi = {10.1007/s10238-024-01391-3}
}
EUVIMED